Articles On Amplia Therapeutics (ASX:ATX)
Title | Source | Codes | Date |
---|---|---|---|
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | ATX | 1 day ago |
Amplia Therapeutics updates on next stage of ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) is progressing thee Phase 2a stage of the ACCENT trial involving its FAK-inhibitor narmafotinib in combination with gemcitabine and abraxane. |
BiotechDispatch | ATX | 4 weeks ago |
Amplia Therapeutics takes step up in pancreatic cancer treatment
Amplia Therapeutics (ASX:ATX) has progressed its ACCENT trial to evaluate narmafotinib, a drug that treats solid tumours in advanced pancreatic cancer patients. The ACCENT trial, conducted in two stages, assesses the safety and efficacy... |
themarketonline.com.au | ATX | 4 weeks ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | ATX | 1 month ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | ATX | 5 months ago |
ASX Health Stocks: Amplia’s pancreatic cancer trial gets boost; Emyria’s MDMA therapy is one step closer
Amplia reports positive data from pancreatic cancer trial Emyria was given endorsement by ethical committee for its TGA application MedAdvisor’s Q1 sales were up 27pc Amplia reports promising data from pancreatic cancer trial Amplia The... |
Stockhead | ATX | 5 months ago |
Amplia Therapeutics mints $2.4m R&D tax benefit
Amplia Therapeutics (ASX:ATX) receives $2.4 million from the government The money comes as part of a national research and development tax incentive The R&D work done relates to the company’s ongoing pancreatic cancer trial... |
themarketherald.com.au | ATX | 6 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | ATX | 6 months ago |
AACR OVARIAN CANCER CONFERENCE PRESENTATION
HIGHLIGHTS Data from preclinical studies in ovarian cancer presented at premier international conference in Boston, USA. Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care... |
FNArena | ATX | 6 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | ATX | 6 months ago |
ASX cancer stocks guide: Here’s everything you need to know
According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W... |
Stockhead | ATX | 7 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | ATX | 7 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | ATX | 7 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | ATX | 7 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | ATX | 8 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | ATX | 8 months ago |
Dr Boreham’s Crucible: Telix Pharmaceuticals
Oncology radiology leader Telix Pharmaceuticals is taking on the US, Tim Boreham reports. By Tim Boreham ASX Code: ((TLX)) Share price: $11.26 Shares on issue: 318,808,268 Market cap: $3.58 billion Chief executive officer: Dr Christian Behr... |
FNArena | ATX | 8 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | ATX | 10 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | ATX | 10 months ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | ATX | 10 months ago |
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
HIGHLIGHTS Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer FOLFIRINOX is the most widely used treatment for pancreatic cancer patients... |
FNArena | ATX | 10 months ago |
ASX Health Stocks: Tissue Repair and Radiopharm jump double digits after US FDA meetings
Tissue Repairs and Radiopharm surge after US FDA meetings Avecho granted application approval by US Patent Office Amplia demonstrated efficacy of its pancreatic drug Tissue Repair to progress to Phase 3 Wound healing specialist Tissue R... |
Stockhead | ATX | 10 months ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | ATX | 11 months ago |
Amplia Therapeutics receives grant to collaborate with CSIRO
Amplia Therapeutics (ASX:ATX) has received grant funding to undertake a research collaboration with Australia’s national science agency CSIRO to develop novel topical formulations of the company’s FAK inhibitors. |
BiotechDispatch | ATX | 11 months ago |
In Case You Missed It: Bumper software revenue, a lithium farm-in and CSIRO research partnership
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | ATX | 11 months ago |
TMH Spotlight: OncoSil Medical (ASX:OSL) treats first patient in Italy, Iceni Gold (ASX:ICL) strikes high grade gold at Guyer
The ASX opened lower this morning, while majority of the sectors dragged. Finance and communications fell 0.5 per cent, while healthcare also took a hit – down 0.13 per cent. However, Amplia Therapeutics (ATX) appeared immune to the... |
themarketherald.com.au | ATX | 11 months ago |
Amplia Therapeutics (ASX:ATX) receives grant funding to support research collaboration with CSIRO
Amplia Therapeutics (ATX) receives grant funding to support research collaboration with Australia’s national science agency, CSIRO The company will work with CSIRO to develop formulations of its small molecule FAK inhibitors that can be... |
themarketherald.com.au | ATX | 11 months ago |
Market Highlights: Debt ceiling climax weighs on markets, Albanese brings home the bacon from G7
The ASX is set to fall modestly lower on Monday on debt ceiling uncertainties Foot Locker plunged 27% after slow sales in Q1 Climate and energy set to be established as the third pillar of the Australia-US alliance Aussie shares are se... |
Stockhead | ATX | 11 months ago |
Amplia Therapeutics says third cohort enrolment completed in ACCENT clinical trial
Amplia Therapeutics (ASX:ATX) has announced the completion of enrolment of the third cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial in frontline patients with pancreatic cancer. |
BiotechDispatch | ATX | 11 months ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | ATX | 11 months ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | ATX | 11 months ago |
Amplia Therapeatuics (ASX:ATX) recruits first patient in cohort three of trial for Pancreatic Cancer
Amplia Therapeutics (ATX) recruits and doses the first patient in cohort three of its ongoing ACCENT trial for pancreatic cancer Under the third cohort, patients will receive an increased dosage of ATX’s AMP945 product, following the sa... |
themarketherald.com.au | ATX | 1 year ago |
ASX Today: Stocks to watch on Wednesday
The ASX is expected to open flat on Wednesday following a muted session on Wall Street. Yesterday, the RBA released its April minutes for when it decided to pause further rates hikes, detailing that it was a close but necessary decision... |
themarketherald.com.au | ATX | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | ATX | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | ATX | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | ATX | 1 year ago |
Amplia Therapeutics (ASX:ATX) appoints Christopher Burns as CEO and MD
Amplia Therapeutics (ATX) appoints Christopher Burns as CEO and Managing Director, effective from December 5Dr Burns has more than 30 years of experience in drug discovery and development and has served in multiple executive positions for p... |
themarketherald.com.au | ATX | 1 year ago |
Vida Ventures MD says it’s a rosy outlook for biotech investment in Australia in the long run
27 new biotech companies listed on the ASX the last two years Australian companies need access to US capital to grow The AusBiotech investment conference kicks off next week in WA The Covid-19 pandemic put Australia’s biotechnology sect... |
Stockhead | ATX | 1 year ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | ATX | 1 year ago |
Amplia Therapeutics (ASX:ATX) finds positive data in AMP886 mice studies to treat AML
Amplia Therapeutics (ATX) releases data from two mice studies, showing potential for its AMP886 drug to reduce cancer in patients with acute myeloid leukaemia (AML)One study showed mice inoculated with MV4-11 cells who were then treated wit... |
themarketherald.com.au | ATX | 1 year ago |
Closing Bell: Small caps cop out, Ode to ODE’s 70pc gain, and we know why Nickel Mines is actually Nickel Industries
ASX 200 gains 1% Small Caps index does the same, but then gives it all back ODE wins and NIC MD Justin Werner: Hengjaya joins world’s best nickel resources The ASX Emerging Companies index (XEC) has given all away its early gains on Mo... |
Stockhead | ATX | 1 year ago |
Dr John Lambert resigns as CEO and MD from Amplia Therapeutics (ASX:ATX)
Dr John Lambert (ATX) resigns as CEO and Managing Director from Amplia Therapeutics, effective NovemberThe company says he will be available to assist with an orderly transition of the role and has commenced the search for a new CEOCommenti... |
themarketherald.com.au | ATX | 1 year ago |
Top 10 at 10: These ASX lithium and rare earths stocks look magnificent on Moo-nday
Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | ATX | 1 year ago |
Closing Bell: Small caps absolutely crush it again; DM1 rises 75% over two sessions of rare earth sci-fi excitement
Small caps burn rest of field. Again. Up 1.8% ASX 200 dips. Again DM1 jumps 75% over two sessions The ASX Emerging Companies (XEC) index has climbed more than 1.8% higher on Wednesday while its erstwhile brethren which measures the favo... |
Stockhead | ATX | 1 year ago |
Dr Boreham’s Crucible: Telix Pharmaceuticals
Telix Pharmaceuticals' prostate cancer imaging product Illucix is quickly conquering the USA, but management at the firm has (much) higher ambitions. ASX Code: ((TLX)) Market cap: $2.02bn Shares on issue: 312,916,341 Chief executive officer... |
FNArena | ATX | 1 year ago |
Closing Bell: Mrs Pelosi goes to Taipei; Pfizer comes back for ResApp
The ASX 200 is down, the XEC surged late, up 1.5% Tech stocks rise, Cons discretionary and energy dragging US Futures flat, Chinese markets higher on Pelosi goes to Taipei day Ahead of the close here in Sydney, US Futures connected to... |
Stockhead | ATX | 1 year ago |
Amplia Therapeutics (ASX:ATX) doses first patient in pancreatic cancer trial
Amplia Therapeutics (ATX) doses its first patient in a clinical trial of AMP945 The trial is designed to enhance the efficacy of gemcitabine/nab-paclitaxel chemotherapy for people with advanced pancreatic cancer undergoing first-line treat... |
themarketherald.com.au | ATX | 1 year ago |
Closing Bell: With great power comes a carefully nuanced distancing from responsibility; the ASX is flat too
The ASX 200 is flat as, the XEC small caps index is down 0.7% It’s RBA day, no real surprises US Futures are lower, Chinese markets sink Local markets are giving back what little they got from morning trade following the reserve bank o... |
Stockhead | ATX | 1 year ago |
Amplia Therapeutics' trial to be presented at major US conference
Amplia Therapeutics (ASX:ATX) has announced that an abstract describing its ACCENT clinical trial of AMP945 in first-line patients with advanced pancreatic cancer has been accepted for presentation at the American Association for Ca... |
BiotechDispatch | ATX | 1 year ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | ATX | 1 year ago |